BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BLRX · as of Sep 30, 2025
Ownership Breakdown
14
Institutional Holders
▼ 5 vs Q2
$104,308
Total Inst. Value
▼ $197,795 vs Q2
4.35M
Shares Outstanding
freeFloat 99.83%
27,595
13F Shares Held
▼ 38,621 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BLRX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 20.2K | 51.15% | 51.15% | $76.36M | Nov 14, 2025 | NEW |
CITADEL ADVISORS LLC pharmaceutical preparations | 10.0K | 25.37% | 25.37% | $37.88M | Nov 14, 2025 | ▼ 4.9K |
UBS GROUP AG pharmaceutical preparations | 6.4K | 16.17% | 16.17% | $24.14M | Nov 13, 2025 | ▲ 6.4K |
MORGAN STANLEY pharmaceutical preparations | 6.0K | 15.07% | 15.07% | $22.50M | May 27, 2026 | ▲ 4.4K |
RHUMBLINE ADVISERS pharmaceutical preparations | 3.1K | 7.77% | 7.77% | $11.60M | Nov 6, 2025 | ▼ 1.2K |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 1.8K | 4.43% | 4.43% | $6.62M | Nov 13, 2025 | — held |
NEMES RUSH GROUP LLC pharmaceutical preparations | 250 | 0.63% | 0.63% | $945,000 | Nov 13, 2025 | — held |
NEWEDGE ADVISORS, LLC pharmaceutical preparations | 107 | 0.27% | 0.27% | $405,000 | Nov 17, 2025 | — held |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 39 | 0.10% | 0.10% | $147,000 | Nov 14, 2025 | NEW |
ROCKEFELLER CAPITAL MANAGEMENT L.P. pharmaceutical preparations | 12 | 0.03% | 0.03% | $45,000 | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
2
Increased
+10.8K shares3
New Positions
first time holders2
Decreased
−6.1K shares9
Sold Out
fully exitedNet shares change (top 50)
+4.7K
+10.8K / −6.1K
Net new holders
-6
3 new / 9 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BLRX insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BioLineRx Ltd. (BLRX) is primarily owned by institutional investors, who hold approximately 0.6% of total shares outstanding. Company insiders own approximately 0.17%, while retail and public investors account for the remaining 99.20%.
The largest institutional shareholder of BioLineRx Ltd. is SUSQUEHANNA INTERNATIONAL GROUP, LLP, holding approximately 20,200 shares — equal to 51.15% of outstanding shares — as of September 30, 2025.
A total of 14 institutional investors currently hold BLRX stock, with a combined institutional value of approximately $104,308 as of the most recent 13F filing period.
Frequently asked questions
BLRX ownershipBioLineRx Ltd. (BLRX) is primarily owned by institutional investors, who hold approximately 0.6% of shares. The largest shareholder is SUSQUEHANNA INTERNATIONAL GROUP, LLP with a 51.15% stake. Company insiders hold 0.17%. Data sourced from SEC Form 13F as of September 30, 2025.